Institute of Science Tokyo · Graduate School of Medical and Dental Sciences · 助教

Research keywordsCancer・Internal・medicine・Oncology・分子生物学・免疫学・血液内科学・腫瘍免疫

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients 2025.03; 16 (1): 140-162. ( DOI )2025
• Suguru Miyazawa, Hiroaki Ono, Hironari Yamashita, Daisuke Asano, Yoshiya Ishikawa, Shuichi Watanabe, Hiroki Ueda, Satoru Aoyama, Naoya Ishibashi, Keiichi Akahoshi, Sadakatsu Ikeda, Minoru Tanabe. Evaluation of therapeutic agent selection based on comprehensive genomic profiling in gastroenteropancreatic neuroendocrine neoplasms. PLoS One. 2025.08; 20 (8): e0325727. ( PubMed , DOI )2025
• Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, Fukuda S, Waseda Y, Tanaka H, Fujii Y. A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU case reports. 2024.09; 7 (5): 395-398. ( PubMed , DOI )2024
• Morikawa, R; Nitta, K; Yasuda, S; Kano, Y; Noji, R; Aoyama, S; Sato, S; Ikeda, S; Okamoto, R; Nagata, M; Mori, T; Suenaga, M. Identification of risk factors for gastrointestinal immune-related adverse events associated with immune check point inhibitors EXPERT OPINION ON DRUG SAFETY. 2024.12; 1-8. ( PubMed , DOI )2024

• 複数の抗原を認識し拡張性を高めたキメラ抗原受容体（CAR）-T細胞療法の開発
• 新規キメラ抗原受容体を用いた革新的ながん治療の開発

• Official profile
• ORCID